T1	Participants 29 48	early breast cancer
T2	Participants 450 640	624 (94%) and 462 (69%), respectively, of 667 postmenopausal women with hormone responsive early breast cancer treated by surgery followed by adjuvant treatment with tamoxifen +/- octreotide
T3	Participants 1626 1675	women with hormone responsive early breast cancer
